Skip to main content
. 2019 Jun 25;10:1377. doi: 10.3389/fimmu.2019.01377

Table 1.

Study design and groups.

Treatment group Experimental biological product and (estimated dose) No. of animals Route of administration Challenge
T01 PBS (Negative control) 8 s/c B. bronchiseptica
T02 Bronchicine CAe (Positive control) 8 s/c B. bronchiseptica
T03 BbBG – 7 (~1 × 107 BG particles) 8 s/c B. bronchiseptica
T04 BbBG – 5 (~1 × 105 BG particles) 8 s/c B. bronchiseptica

PBS, phosphate buffer saline; BbBG, B. bronchiseptica Bacterial Ghosts; s/c, sub cutaneous.